| Name | Title | Contact Details |
|---|---|---|
Chris Radl |
VP R&D / Engineering | Profile |
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.
Algorithme Pharma, Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Inogent is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RSP Nutrition is a company that makes premium nutritional supplements that inspire customers to live healthy, active lifestyles and achieve their fitness goals.
Essential Formulas is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.